4/A: Unicycive Director Sandeep Laumas Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Sandeep Laumas was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc. as part of an equity compensation package.
Summary
- Director Sandeep Laumas received two separate grants of restricted stock units (RSUs) on May 14, 2026.
- The first grant consists of 84,200 RSUs, with 11,694 vesting immediately and the remainder vesting monthly over 31 months starting June 1, 2026.
- The second grant consists of 42,100 RSUs, with 17,542 vesting immediately and the remainder vesting monthly over 7 months starting June 1, 2026.
- All RSUs are payable solely in common stock of Unicycive Therapeutics, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation, which carries no significant signal regarding company performance.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention-focused vesting schedules for the granted equity.
Negatives
- Potential for future shareholder dilution upon the vesting and issuance of the underlying common stock.
Risks
- Continued service risk, as vesting is contingent upon the director's ongoing relationship with the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.
Comparison to Industry Standards
- The use of RSUs as a primary vehicle for director compensation is consistent with standard practices for small-cap biotechnology firms.
- Vesting schedules tied to continued service are typical for maintaining board stability.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation | Grant of restricted stock units to Director Sandeep Laumas. | 05/14/2026 | Standard alignment of director compensation with equity performance. |
Stakeholder Impact
- Shareholders may experience minor dilution as these RSUs vest and convert to common stock.
Next Steps
- Monthly vesting of RSU awards beginning June 1, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of RSU grant transaction. |
| 05/18/2026 | Date of original filing. |
| 06/01/2026 | Commencement of monthly vesting for both RSU awards. |
| 06/15/2026 | Date of current filing signature. |
Keywords
Unicycive Therapeutics, UNCY, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.